Receptors, Tumor Necrosis Factor, Type II

"Receptors, Tumor Necrosis Factor, Type II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A tumor necrosis factor receptor subtype that is expressed primarily in IMMUNE SYSTEM cells. It has specificity for membrane-bound form of TUMOR NECROSIS FACTORS and mediates intracellular-signaling through TNF RECEPTOR ASSOCIATED FACTORS.

Descriptor ID	D047889
MeSH Number(s)	D12.776.543.750.705.852.760.798
Concept/Terms	Receptors, Tumor Necrosis Factor, Type II Receptors, Tumor Necrosis Factor, Type II Receptors, Tumor Necrosis Factor, Member 1B TNF-R2 TNF-R75 TNF-RII TNFR p75 Tumor Necrosis Factor Receptor 75 Tumor Necrosis Factor Receptor 2 TNFR2 Tumor Necrosis Factor Receptor Type 2 Tumor Necrosis Factor Receptor Type II Antigens, CD120b CD120b Antigens TNFRSF1B Receptor Receptor, TNFRSF1B Tumor Necrosis Factor Receptor Superfamily, Member 1B CD 120b Antigen 120b Antigen, CD Antigen, CD 120b CD120b Antigen Antigen, CD120b TNFR p80 TNFR p80 TNF-sR75 TNF-sR75

Below are MeSH descriptors whose meaning is more general than "Receptors, Tumor Necrosis Factor, Type II".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Receptors, Cytokine [D12.776.543.750.705.852]
Receptors, Tumor Necrosis Factor [D12.776.543.750.705.852.760]
Receptors, Tumor Necrosis Factor, Type II [D12.776.543.750.705.852.760.798]

Below are MeSH descriptors whose meaning is related to "Receptors, Tumor Necrosis Factor, Type II".

Below are MeSH descriptors whose meaning is more specific than "Receptors, Tumor Necrosis Factor, Type II".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptors, Tumor Necrosis Factor, Type II" by people in this website by year, and whether "Receptors, Tumor Necrosis Factor, Type II" was a major or minor topic of these publications.

Bar chart showing 22 publications over 15 distinct years, with a maximum of 2 publications in 2007 and 2008 and 2009 and 2011 and 2014 and 2016 and 2017

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1998	0	1	1
2002	0	1	1
2003	0	1	1
2005	0	1	1
2007	0	2	2
2008	0	2	2
2009	1	1	2
2011	1	1	2
2012	0	1	1
2014	2	0	2
2016	1	1	2
2017	0	2	2
2019	0	1	1
2021	1	0	1
2022	1	0	1

Below are the most recent publications written about "Receptors, Tumor Necrosis Factor, Type II" by people in Profiles.

Sander CA, Rush EA, Shi J, Arantes LMRB, Tesi RJ, Ross MA, Calderon MJ, Watkins SC, Kirkwood JM, Ferris RL, Butterfield LH, Vujanovic L. Co-expression of TNF receptors 1 and 2 on melanomas facilitates soluble TNF-induced resistance to MAPK pathway inhibitors. J Transl Med. 2022 Jul 25; 20(1):331.

View in: PubMed
Soliman SA, Haque A, Mason S, Greenbaum LA, Hicks MJ, Mohan C, Wenderfer SE. Cross-sectional study of plasma Axl, ferritin, IGFBP4 and sTNFR2 as biomarkers of disease activity in childhood-onset SLE: A study of the Pediatric Nephrology Research Consortium. Lupus. 2021 Aug; 30(9):1394-1404.

View in: PubMed
Raphael I, Gomez-Rivera F, Raphael RA, Robinson RR, Nalawade S, Forsthuber TG. TNFR2 limits proinflammatory astrocyte functions during EAE induced by pathogenic DR2b-restricted T cells. JCI Insight. 2019 12 19; 4(24).

View in: PubMed
Garudadri S, Woodruff PG, Han MK, Curtis JL, Barr RG, Bleecker ER, Bowler RP, Comellas A, Cooper CB, Criner G, Dransfield MT, Hansel NN, Paine R, Krishnan JA, Peters SP, Hastie AT, Martinez FJ, O'Neal WK, Couper DJ, Alexis NE, Christenson SA. Systemic Markers of Inflammation in Smokers With Symptoms Despite Preserved Spirometry in SPIROMICS. Chest. 2019 05; 155(5):908-917.

View in: PubMed
Baker NL, Hunt KJ, Stevens DR, Jarai G, Rosen GD, Klein RL, Virella G, Lopes-Virella MF. Association Between Inflammatory Markers and Progression to Kidney Dysfunction: Examining Different Assessment Windows in Patients With Type 1 Diabetes. Diabetes Care. 2018 01; 41(1):128-135.

View in: PubMed
Ra SW, Sze MA, Lee EC, Tam S, Oh Y, Fishbane N, Criner GJ, Woodruff PG, Lazarus SC, Albert R, Connett JE, Han MK, Martinez FJ, Aaron SD, Reed RM, Man SFP, Sin DD. Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respir Res. 2017 05 30; 18(1):109.

View in: PubMed
Mok CC, Ding HH, Kharboutli M, Mohan C. Axl, Ferritin, Insulin-Like Growth Factor Binding Protein 2, and Tumor Necrosis Factor Receptor Type II as Biomarkers in Systemic Lupus Erythematosus. Arthritis Care Res (Hoboken). 2016 09; 68(9):1303-9.

View in: PubMed
Wu T, Ding H, Han J, Arriens C, Wei C, Han W, Pedroza C, Jiang S, Anolik J, Petri M, Sanz I, Saxena R, Mohan C. Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study. J Proteome Res. 2016 07 01; 15(7):2102-14.

View in: PubMed
Ungewickell A, Bhaduri A, Rios E, Reuter J, Lee CS, Mah A, Zehnder A, Ohgami R, Kulkarni S, Armstrong R, Weng WK, Gratzinger D, Tavallaee M, Rook A, Snyder M, Kim Y, Khavari PA. Genomic analysis of mycosis fungoides and Sézary syndrome identifies recurrent alterations in TNFR2. Nat Genet. 2015 Sep; 47(9):1056-60.

View in: PubMed
Jialal I, Devaraj S. Comment on Lopes-Virella et al. Baseline markers of inflammation are associated with progression to macroalbuminuria in type 1 diabetic subjects. Diabetes care 2013;36:2317-2323. Diabetes Care. 2014 May; 37(5):e106-7.

View in: PubMed

People

Explore

Similar Concepts

Top Journals